Skip to main content
OpenTrials
Completed

NCT Number: NCT03106181

A Comparison of Cataract Surgery Alone and Cataract Surgery With iStent

This study aims to recruit patients of the Glaucoma Investigative and Research Unit (GIRU) of Royal Victorian Eye and Ear Hospital (RVEEH) with mild to moderate glaucoma who are due to undergo cataract surgery and randomise each to either cataract surgery or combined cataract surgery with iStent Inject® insertion. Only patients who meet the inclusion criteria and none of the exclusion criteria will be recruited. The outcomes measures of the study will be a comparison of: 1) extent of IOP reduction; 2) reduction in number of topical glaucoma medications; 3) patient treatment satisfaction - between the two treatment groups.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Royal Victorian Eye and Ear Hospital

East Melbourne, Victoria, 3002, Australia

About this study

Glaucoma is the commonest cause of irreversible blindness in the world. Treatment centres around lowering intraocular pressure (IOP) and typically includes medication (least invasive), laser, to surgery (most invasive). The gold-standard glaucoma operation is the trabeculectomy. Whilst it is effective at lowering IOP, it is associated with potentially devastating complications including bleb leak, hypotonous maculopathy, blebitis and endophthalmitis. In recent years, minimally- invasive glaucoma surgery (MIGS) has become an increasingly popular option of treating mild to moderate glaucoma. It is usually performed in conjunction with cataract surgery. The iStent (Glaukos Corporation, California, USA) is one of the most commonly utilised MIGS devices in the world and one of two Therapeutic Goods Administration (TGA)- approved MIGS devices in Australia. The iStent Inject® is the second generation iStent device and Australia is one of the first countries in the world to have access to this. So far there are no published randomised controlled trials comparing the effect of cataract surgery alone to combined cataract surgery with insertion of iStent Inject®.

This study aims to recruit patients of the Glaucoma Investigative and Research Unit (GIRU) of Royal Victorian Eye and Ear Hospital (RVEEH) with mild to moderate glaucoma who are due to undergo cataract surgery and randomise each to either cataract surgery or combined cataract surgery with iStent Inject® insertion. Only patients who meet the inclusion criteria and none of the exclusion criteria will be recruited. The outcomes measures of the study will be a comparison of: 1) extent of IOP reduction; 2) reduction in number of topical glaucoma medications; 3) patient treatment satisfaction - between the two treatment groups.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >18 years of age
  • Diagnosis of mild-to-moderate open angle glaucoma
  • Presence of cataract requiring surgery
  • Good understanding of both verbal and written English
  • Able to provide informed consent

Exclusion criteria

  • Recent intraocular surgery within last 3 months
  • Other ocular pathology affecting vision
  • Inability to complete the elements of the study, eg: coma, hemodynamic instability, ventilator dependence, that could be of concern in the investigator's judgment.
  • Non-elective hospitalisation within the past 60 days that could be of concern in the investigator's judgment.
  • Medical illness that in the judgment of the investigator would jeopardise the safe completion of the study. Examples include cancer, chronic inflammatory disease, chronic liver insufficiency, epilepsy, thrombocytosis.

Treatment and study plan

iStent inject®

Device

Insertion of iStent inject®

Phacoemulsification and intraocular lens implant

Procedure

Conventional phacoemulsification cataract surgery and intraocular lens implant

Primary outcomes

  1. Intraocular pressure

    Time frame: Up to 2 years

    Intraocular pressure reduction

  2. Glaucoma medications

    Time frame: Up to 2 years

    Number of glaucoma medications

Secondary outcomes

  1. Treatment satisfaction

    Time frame: Up to 2 years

    Patient treatment satisfaction

Sponsors and collaborators

Lead sponsor

Royal Victoria Eye and Ear Hospital

Other Gov

Collaborators

  • Center for Eye Research Australia
  • Glaukos Corporation

Registry information

Official study title

A Randomised Controlled Trial of Cataract Surgery Versus Combined Cataract Surgery With Insertion of iStent Inject®

Important dates

Study start
2018
Primary completion
2022
Study completion
2022
First posted
Apr 10, 2017
Registry last updated
Aug 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.